APACT: Drug Combinations of Atovaquone-Proguanil (AP) With ACT

Sponsor

Armed Forces Research Institute of Medical Sciences, Thailand (Other)

Overall Status

Recruiting

CT.gov ID

NCT03726593

Collaborator

National Center for Parasitology, Entomology, and Malaria Control (CNM) (Other), Naval Medical Research Unit-2 (NAMRU-2) (Other)

252

Enrollment

Locations

Arms

50.9

Anticipated Duration (Months)

Patients Per Site

1.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Investigators are conducting this study due to recent reports of many of existing malaria drugs becoming less effective for treatment of malaria. The drugs may not always kill all the parasites, therefore not all patients with malaria are being cured. The main objective of the study is to find out which malaria drugs and what drug combinations are still effective in Cambodia, an area of multi-drug resistance where 4-5 artemisinin-based combination therapies have shown inadequate response, below that established by the World Health Organization (WHO). New drug combinations (taking more than one drug for malaria at the same time), as long as well tolerated, can provide cure in patients that harbor parasites not responsive to standard first-line medications. Human genetic testing will be done to identify patients who may have suboptimal response to treatments and to study the differences in human gene expression to explain why some persons are at higher risk of complications during treatment. Markers of drug resistance to commonly used antimalarial drugs will also be evaluated and shared with national malaria program (CNM) to better guide future malaria treatment decisions in Cambodia.

Condition or Disease	Intervention/Treatment	Phase
Plasmodium Falciparum Malaria (Drug Resistant)	Drug: Artesunate and Pyronaridine Drug: Atovaquone Proguanil and Artesunate Pyronaridine Drug: Atovaquone Proguanil and Artesunate Mefloquine	Phase 4

Detailed Description

Efficacy to drugs that are currently available and new antimalarial candidates that are in development are threatened by multidrug resistant (MDR) malaria parasites, widely prevalent in Cambodia. Without effective interventions, MDR malaria can pose a substantial public health threat in the years to come. Therefore, accurate, timely and relevant data on antimalarial drug resistance is of critical importance. Prompt, effective and well-tolerated treatment remains one of the cornerstones in the malaria case management. Recent malaria outbreak in Thailand and rise of malaria cases observed in Cambodia in 2017 has brought to the forefront the urgency with which new drug candidates and new combination drug treatments must be identified; otherwise, patients may be left with ineffective treatments. Lack of available alternatives has a potential to result in significant setback to the recent gains in malaria control and malaria elimination efforts. Innovative approaches to treatment proposed here, using current ACTs in combination with non-ACT drugs, such as atovaquone-proguanil, need to be investigated to assess drug tolerability and overall efficacy when used under combination treatment. By early investment in the studies of drugs such as pyronaridine-artesunate (ASPY), in combination with other antimalarials, and drug combinations proposed under this protocol, this study will try to provide the latest evidence on the interventions that are most likely to work, even in areas of MDR, such as Cambodia, and along the Cambodia-Thai border. It is hoped that our approach for using combination treatments will not only provide more effective treatments, but it might prolong the lifespan of the remaining antimalarials and delay the spread of MDR malaria to neighboring countries.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

252 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Randomized, open-label clinical trial to evaluate the tolerability and clinical and parasitological responses after treatment of Pf and/or mixed infections (Pf/Pv) in volunteers with uncomplicated malaria. The assignment of volunteers will be 1:1:1 for ASPY (Pyramax), AP+ASPY (AP+Pyramax), and AP+ASMQ. All study drug administration will be by directly observed therapy (DOT).Randomized, open-label clinical trial to evaluate the tolerability and clinical and parasitological responses after treatment of Pf and/or mixed infections (Pf/Pv) in volunteers with uncomplicated malaria. The assignment of volunteers will be 1:1:1 for ASPY (Pyramax), AP+ASPY (AP+Pyramax), and AP+ASMQ. All study drug administration will be by directly observed therapy (DOT).

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Multicenter Therapeutic Efficacy Assessment of Pyronaridine-Artesunate (Pyramax®) and New Drug Combinations With Atovaquone-Proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Cambodia

Actual Study Start Date :

Oct 4, 2018

Anticipated Primary Completion Date :

Aug 30, 2022

Anticipated Study Completion Date :

Dec 30, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: ASPY Artesunate-pyronaridine, once daily for three days, following standard weight-based dosing per drug label. All volunteers with P.f monoinfection will receive single dose of primaquine (PQ) (15 mg) for transmission blocking.	Drug: Artesunate and Pyronaridine Standard weight based dosing
Experimental: AP+ASPY Atovaquone-Proguanil (AP) + Artesunate-Pyronaridine (ASPY), once daily for three days, following standard weight-based dosing per drug label for each drug. All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking	Drug: Atovaquone Proguanil and Artesunate Pyronaridine Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.
Experimental: AP+ASMQ Atovaquone-Proguanil (AP) + Artesunate-Mefloquine (ASMQ); ASMQ once daily for three days (D0, D1, D2), following standard weight-based dosing per drug label. Subsequently, volunteers continue their treatment with AP once daily starting on day 3, for three additional days (D3, 4, 5). All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking.	Drug: Atovaquone Proguanil and Artesunate Mefloquine Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)

Arm

Intervention/Treatment

Experimental: ASPY

Artesunate-pyronaridine, once daily for three days, following standard weight-based dosing per drug label. All volunteers with P.f monoinfection will receive single dose of primaquine (PQ) (15 mg) for transmission blocking.

Drug: Artesunate and Pyronaridine

Standard weight based dosing

Experimental: AP+ASPY

Atovaquone-Proguanil (AP) + Artesunate-Pyronaridine (ASPY), once daily for three days, following standard weight-based dosing per drug label for each drug. All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking

Drug: Atovaquone Proguanil and Artesunate Pyronaridine

Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.

Experimental: AP+ASMQ

Atovaquone-Proguanil (AP) + Artesunate-Mefloquine (ASMQ); ASMQ once daily for three days (D0, D1, D2), following standard weight-based dosing per drug label. Subsequently, volunteers continue their treatment with AP once daily starting on day 3, for three additional days (D3, 4, 5). All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking.

Drug: Atovaquone Proguanil and Artesunate Mefloquine

Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)

Outcome Measures

Primary Outcome Measures

42-day polymerase chain reaction (PCR) corrected adequate clinical and parasitological response (ACPR), following treatment with ASPY and new drug combinations (AP+ACTs). [6 weeks]

Secondary Outcome Measures

Prevalence of molecular markers of drug resistance [Day of enrollment and day of malaria recurrence up to 8 weeks]
Drug susceptibility testing of parasite isolates against standard antimalarial drugs [Day of enrollment and day of malaria recurrence up to 8 weeks]
Ex vivo drug susceptibility testing
Pharmakokinetics of each study drug - (Cmax) [multiple time points up to 8 weeks]
Peak plasma concentration (Cmax) for study drugs
Pharmakokinetics of each study drug - (AUC) [multiple time points up to 8 weeks]
Area under the plasma concentration versus time curve (AUC)
Pharmakokinetics of each study drug - volume of distribution [multiple time points throughout 6 weeks of follow up]
volume of distribution for study drugs
Pharmakokinetics of each study drug - (T1/2) [multiple time points up to 8 weeks]
elimination half-life (T1/2) for study drugs
Kaplan Meier survival analysis of asexual blood stage parasitemia and sexual stage gametocytes [6 weeks]
Gametocyte carriage rates on days 0, 1, 2, 3, and weeks 1 through 6 for each treatment arm [Days 0, 1, 2, 3, and weekly, up to week 8]
The incidence of hepatotoxicity events for each treatment arm [Day 3 and week 6]
Alanine aminotransferase (ALT)>5 times the upper limit of normal (ULN) or percent of volunteers meeting the Hy's law definition (ALT or aspartate aminotransferase [AST] >3 x ULN and total bilirubin >2 x ULN) at any post-dose time point within 6 weeks of follow up
Rates of treatment-related adverse events [6 weeks]
Severity of treatment-related adverse events [6 weeks]
Grade 1 - mild, Grade 2 - moderate, Grade 3 - severe, Grade 4- life threatening
Number of participants who say they are willing to take the same drug combination in the future [day 2 and week 6]
Point efficacy with 95% Confidence Interval against blood stage malaria infection classified according to the WHO malaria treatment outcome classifications (ETF, LTF, LCTF, LPTF) [4 weeks, 6 weeks, and 8 weeks]
Incidence of Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency [Enrollment]
Comparative incidence of G6PD deficiency in the study population as determined by G6PD rapid-diagnostic tests (RDTs) and quantitative tests, to include sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) for each of the point-of-care tests against 10%, 30%, and 60% thresholds of normal G6PD activity
Number of infected mosquitos following membrane feeding [Day 0, Day 3, Day 7, and on day of malaria recurrence up to 8 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Understands Khmer spoken language
Male or female (18 to 70 years old)
Microscopic confirmation of asexual stages of Pf or mixed infection with Pf, with baseline asexual parasite densities between 100/µL to 200,000/µL
Able to take oral medications
Hemoglobin on day of enrollment ≥9.0 g/dL
Agree to follow-up for the anticipated study duration, including a minimum of 3 nights at the medical treatment facility (inpatient hospitalization) and weekly follow-up visits for at least 6 weeks
If the volunteer is on active duty in the military, the volunteer has written permission from their supervisor or states to have been authorized by his/her supervisor or the local commander to participate; and allow study staff to contact their supervisor to confirm this information

Exclusion Criteria:

Known allergic reaction to any of the study drugs or history of severe intolerance to any of the antimalarials used in this study.
Pregnant or lactating females and females of childbearing potential who do not agree to use an acceptable form of contraception during the study period and for 6 weeks following the last dose of the study drug.
Symptoms of severe vomiting (inability to tolerate oral fluids or oral medications during the previous 8 hours or vomiting >3 times in the last 24 hrs).
Diagnosis of severe malaria
Abnormal liver function tests i.e AST or ALT or total bilirubin > 1.5 upper limit of normal (ULN) with nausea AND right upper quadrant abdominal pain OR jaundice on exam
Isolated AST or ALT or Total Bilirubin >2x ULN
Known significant cardiovascular, liver or renal abnormality or any other clinically significant illness, which in the opinion of the investigator would place the volunteer at significantly higher risk
Treatment for malaria within the last 4 weeks
Unable to provide informed consent
Judged by the investigator to be otherwise unsuitable for study participation (to include, but not limited to, taking other medications that are known to cause serious drug-drug interactions with the study drugs, as determined by the study physician, or having suspected medical condition or taking other drugs that may affect test results interpretation or put the volunteer at much higher risk)